Markets:

Overview

News

Currencies

International

Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

77.12 -1.39 (-1.77%)

Streaming Delayed Price Updated: 3:12 PM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

A Peek at ANI Pharmaceuticals's Future Earnings ↗

November 07, 2024

Via Benzinga

Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know ↗

October 22, 2024

Via Benzinga

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential ↗

October 11, 2024

Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial...

Via Benzinga

Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights ↗

October 11, 2024

Via Benzinga

In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals ↗

September 17, 2024

Via Benzinga

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗

September 11, 2024

Via Benzinga

Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts ↗

April 23, 2024

Via Benzinga

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts ↗

March 05, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

ANI Pharmaceuticals's Earnings Outlook ↗

February 28, 2024

Via Benzinga

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

September 11, 2024

From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.

Via Business Wire

ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)

July 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Expert Ratings for ANI Pharmaceuticals ↗

October 19, 2023

Via Benzinga

Analyst Expectations for ANI Pharmaceuticals's Future ↗

September 13, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals ↗

August 21, 2023

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)

July 01, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

June 26, 2024

Via Benzinga

Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close ↗

June 25, 2024

Via Benzinga

Topics Stocks

Where ANI Pharmaceuticals Stands With Analysts ↗

July 21, 2023

Via Benzinga

Looking Into ANI Pharmaceuticals's Return On Capital Employed ↗

May 23, 2023

Via Benzinga

Why Is Alimera Sciences (ALIM) Stock Up 77% Today? ↗

June 24, 2024

Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.

Via InvestorPlace

Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal ↗

June 24, 2024

ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close...

Via Benzinga

ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 10, 2024

ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Alphabet, Dover And 2 Other Stocks Insiders Are Selling ↗

March 11, 2024

The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Drug Maker Organon Stock Scores Relative Strength Upgrade ↗

February 28, 2024

In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.

Via Investor's Business Daily

Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know ↗

February 16, 2024

Via Benzinga

Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today? ↗

November 08, 2023

ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the

Via Benzinga

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning

August 23, 2023

Via Investor Brand Network

7 A-Rated Biotech Stocks for Your August Buy List ↗

August 17, 2023

Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.

Via InvestorPlace

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.